Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Acthrel
2. Corticorelin Ovine
1. Corticorelin Ovine
2. 79804-71-0
3. Ovine Crh
4. Ovine Acth Releasing Factor
5. Ovine Crf 41
6. Ovine Corticotropin-releasing Factor
7. Corticotropin-releasing Factor (ovine)
8. Corticotropin-releasing Factor (sheep)
9. Amunine
10. Sheep Corticotropin-releasing Factor (1-41)
11. Corticotropin-releasing Factor (sheep Hypothalamus)
12. Ovine Crf
13. Amunin
14. Ocrh
15. Ovine Corticotropin-releasing Hormone
16. Unii-y124tz0513
17. Corticotropin-releasing Hormone, Ovine
18. Corticorelin Triflutate
19. Dtxsid90229925
20. Sheep Corticotropin-releasing Factor
21. Db09067
22. Y124tz0513
23. S-79804-71-0
| Molecular Weight | 4670 g/mol |
|---|---|
| Molecular Formula | C205H339N59O63S |
| XLogP3 | -18.6 |
| Hydrogen Bond Donor Count | 66 |
| Hydrogen Bond Acceptor Count | 71 |
| Rotatable Bond Count | 161 |
| Exact Mass | 4669.4924539 g/mol |
| Monoisotopic Mass | 4667.4857443 g/mol |
| Topological Polar Surface Area | 2010 Ų |
| Heavy Atom Count | 328 |
| Formal Charge | 0 |
| Complexity | 11500 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 45 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Corticorelin is indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.
FDA Label
In normal subjects, intravenous administration of corticorelin results in a rapid and sustained increase of plasma ACTH levels and a near parallel increase of plasma cortisol. In addition, intravenous administration of corticorelin to normal subjects causes a concomitant and prolonged release of the related proopiomelanocortin peptides - and -lipotropins ( -and -LPH) and -endorphin ( -END).
Absorption
Plasma ACTH levels in normal subjects increased 2 minutes after injection of corticorelin doses of 0.3 mcg/kg and reached peak levels after 10-15 minutes. Plasma cortisol levels increased within 10 minutes and reached peak levels at 30 to 60 minutes.
Volume of Distribution
The mean volume of distribution for IR-corticorelin is 6.2 0.5 L
Clearance
95 11 L/m2/day
Plasma half-lives for IR-corticorelin are 11.6 1.5 minutes (mean SE) for the fast component and 73 8 minutes for the slow component.
Corticorelin is a potent stimulator of adrenocorticotropic hormone (ACTH) release from the anterior pituitary. It is used as a diagnostic agent to evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion.
ABOUT THIS PAGE
A Corticorelin ovine triflutate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Corticorelin ovine triflutate, including repackagers and relabelers. The FDA regulates Corticorelin ovine triflutate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Corticorelin ovine triflutate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Corticorelin ovine triflutate supplier is an individual or a company that provides Corticorelin ovine triflutate active pharmaceutical ingredient (API) or Corticorelin ovine triflutate finished formulations upon request. The Corticorelin ovine triflutate suppliers may include Corticorelin ovine triflutate API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Corticorelin ovine triflutate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Corticorelin ovine triflutate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Corticorelin ovine triflutate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Corticorelin ovine triflutate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Corticorelin ovine triflutate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Corticorelin ovine triflutate suppliers with NDC on PharmaCompass.
Corticorelin ovine triflutate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Corticorelin ovine triflutate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Corticorelin ovine triflutate GMP manufacturer or Corticorelin ovine triflutate GMP API supplier for your needs.
A Corticorelin ovine triflutate CoA (Certificate of Analysis) is a formal document that attests to Corticorelin ovine triflutate's compliance with Corticorelin ovine triflutate specifications and serves as a tool for batch-level quality control.
Corticorelin ovine triflutate CoA mostly includes findings from lab analyses of a specific batch. For each Corticorelin ovine triflutate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Corticorelin ovine triflutate may be tested according to a variety of international standards, such as European Pharmacopoeia (Corticorelin ovine triflutate EP), Corticorelin ovine triflutate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Corticorelin ovine triflutate USP).
LOOKING FOR A SUPPLIER?
